Serum-glucocorticoid-inducible kinase 1 confers protection in cell-based and in \textit{in vivo} neurotoxin models via the c-Jun N-terminal kinase signaling pathway

Sarah Iqbal, Shannon Howard and Philip V. LoGrasso

Department of Molecular Therapeutics and Translational Research Institute, The Scripps Research Institute, 130 Scripps Way #2A2, Jupiter, Florida 33458

Correspondence: lograsso@scripps.edu
Abstract

Serum glucocorticoid kinase 1 (SGK1) has been shown to be protective in models of Parkinson’s disease, but the details by which it confers benefit is unknown. The current study was designed to investigate the details by which SGK1 confers neuroprotection. To do this we employed a cellular neurodegeneration model to investigate JNK signaling and endoplasmic reticulum (ER) stress induced by 6-hydroxydopamine. SGK1 adenovirus was created and used to over-express SGK1 in SHSY5Y cells and dexamethasone was used to increase endogenous expression of SGK1. Oxidative stress, mitochondrial dysfunction, and cell death were monitored to test the protective effect of SGK1. To investigate the effect of SGK1 over-expression in vivo, SGK1 adenovirus was injected into the striatum of mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and protection of dopaminergic neurons was quantitatively assessed by tyrosine hydroxylase immunohistochemistry. SGK1 over-expression was found to decrease reactive oxygen species generation, alleviate mitochondrial dysfunction, and rescue cell death in vitro and in vivo by inactivating MKK4, JNK, and GSK3β and thereby decreasing ER and oxidative stress. These results suggest therapeutic strategies for activation of SGK1 may have the potential to be neuroprotective by deactivating the JNK and GSK3β pathways.
Introduction

Serum-glucocorticoid-inducible kinase 1 (SGK1) belongs to the AGC family of kinases and has been shown to have various cellular functions including the promotion of cell survival (1–3). SGK1 is activated by insulin and growth factors via phosphoinositide 3-kinase; PI3K, the 3-phosphoinositide-dependent kinase; PDK1, and the mammalian target of rapamycin mTORC2 (4, 5). SGK1 shares its functions and some substrates with another kinase from the AGC family, protein kinase B (PKB/Akt). Akt, like SGK1 has been shown to mediate cell survival through various signaling cascades and gets activated by wide range of extracellular stimuli (6). SGK1 lacks the pleckstrin homology (PH) domain that tethers Akt to the plasma membrane, making SGK1 more accessible to cytosolic and nuclear sites and thereby providing it with cellular functions and substrates that do not overlap with Akt (1, 6). SGK1 plays a protective role in oxidative stress conditions as siRNA knockdown of SGK1 has shown an increase in oxidative stress-induced cell death in HEK293 cells (7). Oxidative stress is a hallmark of neurodegenerative disorders, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD) (8). In a study published in 2005 by Schoenebeck et al., upregulation of SGK1 is seen in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model and in a transgenic model of ALS (SOD1:G93A), and protection from cell death was observed for animals treated with dexamethasone, which is known to upregulate SGK1 expression, prior to treatment with the neurotoxin (1). In another study, analysis of cortical tissue from patients with severe Alzheimer’s disease (AD), showed an increase not only of SGK1 activity but also of its substrates, N-myc downstream regulated gene 1 (NDRG1) and forkhead box 3a protein (FoxO3a) (9–12). SGK1 shares the latter substrate with Akt. Two recent studies have shown a neuroprotective role for SGK1 in a 6-hydroxydopamine
(6-OHDA) neurotoxin mouse model and in an ischemia reperfusion rat model (13, 14). These findings underscore the importance of SGK1 in neurodegeneration but the details of signaling molecules that contribute to neuroprotection are not well defined.

The c-Jun N-terminal kinases (JNK) are mitogen-activated protein (MAP) kinases responsive to physiological and environmental stress. JNK activation has been observed in various neurodegenerative disorders where the JNK signaling cascade has been shown to cause neuronal cell death (15–19). Importantly, postmortem studies, along with MPTP and 6-OHDA animal models of neurodegeneration showed an important role for JNK in the disease pathogenesis (15, 16, 19). There is very little literature which links JNK and SGK1. In 2007 Kim et al., utilized HEK293 cells to show by Western analysis that SGK1-mediated phosphorylation of MKK4 on Serine80 results in abrogation of MKK4 binding to JNK and thereby inhibits the JNK signaling cascade (20). In 2011 Roger Davis and colleagues utilized primary cerebellar granular neurons (CGNs) from compound JNK deficient mice to identify JNK as a negative regulator of FoxO-dependent autophagy in neurons. FoxO activation in neurons leads to the expression of pro-apoptotic BH3-only protein (Bim). Bim gets phosphorylated by JNK which leads to its dissociation from pro-survival protein, Mcl-1, leading to apoptosis (21). SGK1, in parallel with Akt, has also been shown to negatively regulate the activation and pro-apoptotic function of FoxO proteins (12). Another cellular event where SGK1 and JNK pathways converge, involves an important cellular kinase, Glycogen synthase kinase 3 β (GSK3-β). SGK1 has been shown to phosphorylate and inhibit activity of GSK3β in mouse dendritic cells (22). In a separate pro-apoptotic pathway, JNK phosphorylates Mcl-1 and primes it for phosphorylation by GSK3-β, which ultimately leads to the proteosomal degradation of Mcl-1(23). Therefore, these studies suggest a crosstalk between JNK and SGK1/Akt signaling cascades would define cellular fate in
stress conditions. These intriguing observations led us to hypothesize that SGK1 activation may indeed exert its neuroprotective effects via impacting the JNK pathway. To test this hypothesis we established 6-OHDA cell culture models and studied the impact of over-expression of SGK1 in an MPTP animal model of neurodegeneration to establish the link between SGK1 and JNK and to understand the mechanism by which SGK1 may exert its neuroprotective effect. The main findings from our study showed that SGK1 over-expression rescued neurotoxin-induced mitochondrial dysfunction and subsequent cell death. It did this by regulating the expression of ER and mitochondrial stress marker proteins and by inactivating JNK and GSK3β.

**Materials and methods**

**Kinase-Glo® phoshorylation assay**

Recombinant substrate, inactive MKK4 (Millipore) was diluted to various concentrations in JNK activity buffer (25 mM HEPES, pH 7.4, 10 mM MgCl2, 2 mM dithiothreitol (DTT), 1 mg/mL BSA, and 1 µM ATP). The reaction was initiated with the addition of 0.75 µM active SGK1 (GeneTex). The reaction was incubated at 30 °C for 60 min. The reaction was stopped by the addition of 50 mM EDTA. The reaction was combined with the Kinase-Glo® reagent (Promega) at a 1:1 ratio and then incubated at RT for 10 min. Luminescence was monitored on a Spectromax M5e plate reader (Molecular Devices) with an integration of 500 ms. ATP quantitation was determined based on values interpolated onto an ATP standard curve. Data are reported as percent SGK1 activity based on uninhibited, active SGK1 substrate phosphorylation.

**Cell Culture and treatments**

SH-SY5Y cells (ATCC) were grown at normal cell culture conditions (37°C and 5% CO2) in DMEM/F:12 (Invitrogen) supplemented with 10% fetal bovine serum and
penicillin/streptomycin. To assure that the cells were actively growing, only cells at ~80% confluency and between passages five and fifteen were used in our experiments. Cells were treated with 35 µM 6-OHDA solubilized in dimethyl sulfoxide (DMSO) for 5 h for the different analyses. Cells were treated with 10 µM dexamethasone for 24 h prior to neurotoxin treatment to induce SGK1 expression. JNK inhibitor, SR-3306 and Akt inhibitor MK-2206 (Selleck Chemicals) were added to cells 1 h before the treatment with the neurotoxin.

**Adenoviral-mediated SGK1 expression**

Adenovirus-mediated over-expression of SGK1 was achieved using adenovirus particles purchased from Vector Biolabs. The viral backbone was adenoviral-Type 5 (dE1/dE3) with a synapsin promoter and YFP tag to visualize the cells/tissue after the adenoviral infection. SH-SY5Y cells were infected with a MOI (multiplicity of infection) of 5.

**Mitochondrial Superoxide Production**

Mitochondrial superoxide generation was monitored by MitoSOX Red (Invitrogen) fluorescence. SH-SY5Y cells (50,000 cells/well) were seeded into black-walled, clear-bottomed 96 well plate. After the indicated time for treatments, cells were stained with 2.5µM MitoSOX Red for 25 minutes under growth conditions. The cells were washed twice in Hank’s Buffer Salt Solution (HBSS), and placed in pre-warmed HBSS for imagining. MitoSOX Red fluorescence was detected by exciting the fluorophore at 510nm and monitoring the emission at 580nm on a SpectraMax e5 plate reader (Molecular Devices). Mitochondrial superoxide was normalized to cell abundance by staining the cells with Hoechst 33342 (excitation: 350nm; emission: 450nm). Rotenone was used as a positive control for superoxide generation. Cells were treated with 100nM rotenone for 24 hr to generate a quality signal.
Mitochondrial Membrane Potential

Mitochondrial membrane potential was monitored using the JC-1 dye kit (Cayman Chemical). Cells were seeded in a 96-well black-walled, clear-bottomed plate as described in MitoSOX™ staining above. The cells were then stained with 5mM JC-1 for 20 minutes as indicated in the manufacturer’s protocol. The cells were washed 3 times in HBSS, and covered in pre-warmed HBSS for fluorescence measurements. The green JC-1 species were detected by exciting at 460nm and monitoring emission at 488nm. JC-1 staining was normalized to Hoechst 33342 staining.

Cell Viability

Cell viability of SH-SY5Y cells was monitored by MTT assay (Cayman Chemical). Cells (50,000 cells/well) were seeded in a 96-well plate (clear bottom) and treated as described in the text. At the culmination of each treatment the cells were treated with the MTT reagent. Absorbance was monitored in a SpectraMax e5 plate reader (Molecular Devices).

Cell lysis and Western Blot Analysis

SH-SY5Y (1 x 10^5) cells were plated on a 6-well plate. To acquire protein for Western blot analysis after an experiment, cells were washed twice in PBS. Cell lysis buffer (Cell signaling technology) supplemented with protease inhibitors (1 mm PMSF and 1x Halt Protease Inhibitor cocktail, Thermo Scientific) and 1x phosphatase inhibitors (Halt Phosphatase Inhibitor cocktail, Thermo Scientific) was added to the cells. Cells were incubated in lysis buffer at 4 °C for 5 min while rocking gently. Cells were scraped from the culture surface and transferred to a microcentrifuge tube. Following 2min incubation on ice, the cells were disrupted by brief sonication. The cell lysate was centrifuged at 14,000 × g for 15 min to remove cellular debris.
The concentration of protein in the supernatant was quantified by BCA analysis using the Pierce kit protocol. For Western blot analysis, proteins (25 µg) were resolved by SDS-PAGE, and transferred to nitrocellulose membranes for 1.5 h. Membranes were incubated with blocking buffer (SuperBlock Blocking Buffer, Thermo scientific) for 1 h at room temperature or overnight at 4 °C. After 2 h of incubation with a secondary antibody linked to HRP, membranes were visualized using an ECL detection system (Thermo scientific). The antibodies used for Western blot analysis were: Phospho-JNK (Cell Signaling Technology #9255), Phospho-c-Jun (Cell Signaling Technology #3270), Hsp70 (Cell Signaling Technology #4876), MKK4 (Cell Signaling Technology #3346) Phospho-MKK4 Ser257/Thr261 (Cell Signaling Technology #9156), Phospho-MKK4 Ser80 (Cell Signaling Technology #9155), Phospho-MKK7 (Cell Signaling Technology #4171), Phospho-Akt (Cell Signaling Technology #4060), SGK1 (Cell Signaling Technologies #12103), Phospho-SGK1 (Cell Signaling Technologies #5599), BiP (Cell Signaling Technologies #3183) α-Tubulin (Cell Signaling Technology #2125), SOD1 (Cell Signaling Technologies #4266), secondary anti-rabbit IgG, HRP-linked (Cell Signaling Technology #7074), secondary anti-mouse IgG, HRP-linked (Cell Signaling Technology #7076). The primary antibodies were used at a dilution of 1:1000 according to the manufacturer’s instructions. The secondary antibody was used at a dilution of 1:2000.

**Replicates and Statistics**

For each Western blot, three biological replicates were acquired. For cell viability assays, mitochondrial superoxide detection, and mitochondrial membrane potential, three sample replicates were measured for the three biological replicates obtained for each treatment. Finally,
all statistics displayed were performed using the Student’s T-test of significance. A p-value of 0.05 was used to determine significance.

RT-PCR analysis of SH-SY5Y cells

Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). One microgram of RNA was reverse transcribed using the Omniscript® Reverse Transcription kit (Qiagen) using the reverse primer 5’-ACGAACTACCCGACCCTTAACCCA.

Adenovirus injections in mice

Eleven week old male C57BL/6J mice (Jackson Laboratories) weighing in the range of 25-30 g were used. Mice were acclimated for 1 week prior to initiation of study. Mice were anesthetized via an intraperitoneal injection of Ketamine and Xylazine and placed into a stereotaxic frame (Stoelting) with the head positioned flat. Unilateral injections of SGK1 adenovirus were made into the right striatum at 1.5 mm, 2.0 mm, and 2.5 mm mediolateral from bregma with two depths at 3.6 mm and 3.0 mm dorsoventral below the dura for a total of 6 points. A volume of 1 µl of virus at a concentration of 1x10^10 virus particles (vp) or corresponding saline alone was injected with a 30-gauge needle and an automatic pump (Stoelting) at each coordinate at a rate of 0.5 µl/min for a total of 6 µl (n=17 for both saline and SGK1 injections). The needle was left in place for 3 min following each injection before being withdrawn to prevent backflow. Gene expression was allowed to proceed for 21 days until the mice were challenged with an acute MPTP-lesion regimen.

Immunohistochemistry

Animals were sacrificed by an overdose of ketamine and xylazine followed by cardiac perfusion with 0.9% saline followed by 4% paraformaldehyde in a 0.1 M sodium phosphate buffer, pH 7.4.
The brains were removed and further post-fixed in 4% paraformaldehyde at 4 °C for 1 day, followed by cryoprotection in 30% sucrose for 3-4 days. Brains were embedded and frozen in optimal cutting temperature compound and stored frozen at −80 °C until sectioning. Symmetrical 40-µm-thick sections were cut on a cryostat (Leica CM3050S) between approximately −2.46 and −4.36 mm bregma for approximately 48 sections. Every other section (~21–24 sections) was processed for immunohistochemistry. Free-floating sections were pretreated in 0.3% H$_2$O$_2$ in tris-buffered saline (TBS) for 15 minutes and in blocking solution (4% bovine serum albumin (BSA) in TBS containing 0.1% Triton X-100) for 1 h at room temperature. In between steps, sections were washed three times for 15 minutes in TBS with 0.1% Triton X-100. For proper identification of the SNpc, all sections were incubated overnight at 4 °C with polyclonal rabbit anti-tyrosine hydroxylase (TH) (1:500; Abcam ab112) in 4% BSA in TBS containing 0.1% Triton X-100. Sections were then washed with TBS containing 0.1% Triton X-100 and incubated with anti-rabbit secondary antibody (1:500; Alexa Fluo 488) in 4% BSA in TBS containing 0.1% Triton X-100 for 2 h at room temperature in the dark. In between steps, sections were washed three times for 15 minutes in TBS. Sections were mounted on superfrost plus slides, and a drop of fluoroshield mounting medium with DAPI (1:4) was applied to each section. Slides were coverslipped, sealed with nail polish, and stored at 4 °C.

**Detection of SGK1, TH, and p-c-jun**

SGK1 expression in the SNpc was recognized via a yellow fluorescent tag (Vector Biolabs Ad-Syn-hSGK1_v2-YFP) in one section (bregma -3.0 mm) from each group used for immunohistochemical staining of TH neurons for stereological counting. A YFP filter (Olympus #U-MF2) was used for detecting SGK1 expression at the same exposure time for each group. A
Texas Red filter was used for detecting TH in the same section for detecting SGK1 in a similar manner.

From a separate set of mice unilaterally injected with SGK1 adenovirus, 20 µm sections from the SNpc (bregma -3.0 mm) from each group were double immunofluorescent stained for p-c-jun and TH. Free-floating sections were pretreated in 0.1% H₂O₂ in tris-buffered saline (TBS) for 5 minutes and in blocking solution (4% bovine serum albumin (BSA) in TBS containing 0.1% Triton X-100) for 1 h at room temperature. In between steps, sections were washed three times for 15 minutes in TBS with 0.1% Triton X-100. Sections were incubated overnight at 4 °C with polyclonal sheep anti-tyrosine hydroxylase (1:500; Abcam ab113) and rabbit anti-p-c-jun Ser73 (1:100; Cell Signaling #9164) in 2% BSA in TBS containing 0.1% Triton X-100. Sections were then washed with TBS containing 0.1% Triton X-100 and incubated with anti-sheep and anti-rabbit secondary antibody (1:500; Life technologies A11015 and A11012, respectively) in 2% BSA in TBS containing 0.1% Triton X-100 for 2 h at room temperature in the dark. Sections were washed three times for 15 minutes in TBS and then mounted on superfrost plus slides for imaging.

**MPTP Challenge and Stereological Counting of TH+ Dopaminergic Cells**

The acute MPTP-lesion regimen, immunostaining of TH, stereological evaluation of TH positive cells in the SNpc, and safety precautions as outlined by Jackson-Lewis and Przedborski and Hunot et al. were followed (16, 24). Mice were injected intraperitoneally (i.p.) four times at 2 h intervals over 1 day with 18 mg/kg MPTP-HCl (Sigma) dissolved in 0.9% saline or a corresponding volume of saline alone. Mice were sacrificed 7 days after the MPTP administration and evaluated for counting of SNpc dopaminergic neurons (n=4 for vehicle group for MPTP (Saline + Saline), n=4 for vehicle group for SGK1 (SGK1 + Saline), n=13 for MPTP
group (Saline + MPTP), and n=13 for SGK1 group (SGK1 + MPTP). Beginning at bregma -2.70, brains were sectioned at 40 µm for 48 sections, discarding every other section until bregma-4.04. Of the 28 sections, 12 sections between bregma -2.80 and -3.80 were counted. Unbiased stereological counting by a blinded investigator of TH positive cells in the SNpc was quantitated ((SEM) using the Stereo Investigator (v 8.0) software program (Microbrightfield). Statistical analysis of the TH counting data was performed utilizing the Mann-Whitney U test.

Results

**SGK1 is upregulated in response to neurotoxic stress and its over-expression rescues 6-OHDA-induced mitochondrial dysfunction and cell death in SH-SY5Y cells**

In order to assess whether the expression profile of SGK1 was altered in response to induced neurodegeneration, SH-SY5Y neuroblastoma cells were treated with 35 µM 6-OHDA for varying amounts of time to induce neurotoxic stress and death. Treatment with 6-OHDA showed increases in SGK1 mRNA levels over time (Figure 1 A). Western immunoblot analysis of SH-SY5Y cells treated with 6-OHDA showed an increase in endogenous SGK1 protein expression with time (peaking at 24 hr) and a corresponding increase in levels of phospho-SGK1 Ser80 was also observed (Figure 1 B). These observations corroborate previous studies in *in vivo* MPTP and transgenic ALS mouse models as well as postmortem brain sections from AD and PD patients where an increased SGK1 expression at both mRNA and protein level has been observed (1, 2, 25).

We next investigated the role of SGK1 in mitochondrial dysfunction by measuring generation of mitochondrial ROS and changes in the mitochondrial membrane potential caused by 6-OHDA injury to the cells. Cell death was also measured. Endogenous SGK1 expression was induced in
SH-SY5Y cells by treatment with 10 µM dexamethasone, which has been shown to upregulate transcription and expression of SGK1 (26). Treatment with dexamethasone showed protection from neurotoxin-induced mitochondrial dysfunction and cell death (Figure 1 C, D & E) in a similar magnitude as the protection seen from the selective JNK inhibitor SR-3306. Since SGK1 shares various cell regulatory roles with Akt, an Akt allosteric inhibitor, MK2206 was added to the cells over-expressing SGK1 and prior to adding the neurotoxin to determine whether the protective effects of SGK1 were mainly due to its over-expression. The data showed that neuroprotection was a result of dexamethasone-induced SGK1 over-expression in these cells and the absence of Akt activity did not significantly increase cell death, therefore suggesting that SGK1 compensated for Akt activity in cells undergoing stress (Fig. 1 E & F).

To further elucidate the role of SGK1 in neuroprotection, Type 5 (dE1/E3) adenovirus (AdV-SGK1) was prepared to induce SGK1 expression in SHSY5Y cells. Immunofluorescence images from 6-OHDA-treated SHSY5Y cells showed that adenoviral-induced SGK1 over-expression in these cells was able to reduce neurotoxin-mediated mitochondrial ROS compared to PBS/6-OHDA (Figure 2A) in a manner similar to the reduction seen with JNK inhibition by SR-3306. A similar reduction in mitochondrial ROS has been published by our lab by a JNK inhibitor SR-3306 (15, 19), which was used as a positive control in our studies (Fig. 2A, last panel). Quantitative analysis of MitoSOX™ Red and JC-1 staining revealed that mitochondrial superoxide levels and membrane depolarization were raised by treatment with 35 µM 6-OHDA and alleviated in cells treated with the SGK1 adenovirus prior to treating them with the neurotoxin (Fig. 2 B & C). Similar effect was seen for the viability of these cells (Fig. 2D). Use of the Akt inhibitor, MK2206 showed the same results as that for AdV-SGK1 treatment (Fig. 2D), indicating Akt activity compensation by AdV-SGK1-induced SGK1 expression. These
studies show an important role of SGK1 in rescuing neuronal cells from mitochondrial dysfunction and cell death induced by a neurotoxin. Thus, cells over-expressing SGK1, induced by either the adenovirus or dexamethasone, showed a 2-fold decrease in mitochondrial ROS production, membrane depolarization and rescued them from 6-OHDA-induced cell death.

**Over-expression of SGK1 in SH-SY5Y cells regulate 6-OHDA-induced changes in cellular stress marker proteins**

Mitochondrial dysfunction, ER stress triggered by unfolded protein response, and subsequent cell death are preceded by expression and activation of important regulatory proteins such as, heat shock protein 70 (Hsp70); ER stress marker protein, binding immunoglobulin protein, BiP; mitochondrial stress marker, superoxide dismutase, SOD1, and various others (27–32). ER and cellular stress marker proteins such as BiP and Hsp70 have been shown to have elevated expression levels in response to toxic stress in various neurodegenerative disorders and many reports have detailed the relationship between JNK and Hsp70 (28, 29, 33–35). Mitochondrial protein SOD1 has been implicated in ALS and its activity is critical against oxidative stress, a hallmark of various neurodegenerative diseases (36). To understand the role for SGK1 in cellular stress and investigate the relationship between SGK1 and JNK we measured many of these stress markers in our cell system. Western blot analysis of SH-SY5Y cells treated with 35 µM 6-OHDA for 5 h showed an increase in the expression of BiP (Fig. 3A) and Hsp70 (Fig. 3B) and a decrease in SOD1 (Fig. 3C) protein levels as expected, under cellular stress conditions. Expression of BiP and Hsp70 was rescued in cells over-expressing SGK1 induced by either Dex or AdV-SGK1 (Fig. 3 A&B). Inhibition of JNK activity by SR-3306 in these cells also rescued the expression of these ER stress marker proteins and restored SOD1 levels. These data suggest that SGK1 rescues neurotoxin-induced cellular stress by directly or indirectly regulating the expression of these proteins that have been implicated in various neurodegenerative disorders.
AdV-SGK1-induced expression in SH-SY5Y cells inhibits its downstream substrates, FoxO3a and NDRG-1

The mechanism by which SGK1 confers neuroprotection is not well known and it could potentially be via various cell signaling pathways. Two well-recognized substrates of SGK1 are NDRG-1 and FoxO3a (6, 9). The former is exclusively a substrate of SGK1, whereas the latter also gets phosphorylated by Akt. SGK1 phosphorylation of NDRG-1 has been shown to prime it for phosphorylation by GSK3β but there is not sufficient information available about the biological consequences of NDRG-1 phosphorylation by SGK1 (10, 11, 22). To study this in vitro we infected SHSY5Y cells with AdV-SGK1 and monitored phosphorylation levels of NDRG1 and FoxO3a. Figure 4 shows there was a marked increase in expression of phospho-NDRG-1 and phospho-FoxO3a in SH-SY5Y cells treated with AdV-SGK1. These higher expression levels coincided with the neuroprotective effects of SGK1 in these cells as described in the previous sections (Figures 1-3). As noted previously, over-expression of SGK-1 compensated for the absence of Akt activity and as such phospho-FoxO3a levels were not changed in the presence of an Akt inhibitor (data not shown). These studies substantiate that one of the ways by which SGK1 exerts its pro-survival effects are by phosphorylating and inhibiting these substrates which are key proteins for regulating apoptotic events in neurons.

SGK1 rescues the degradation of cell survival protein Mcl-1 and its phosphorylation by inactivating GSK3β in SH-SY5Y cells

Because GSK3β and Mcl-1 are regulated by SGK1 we investigated the protective effects of SGK-1 over-expression on 6-OHDA-induced phosphorylation of GSK3β and Mcl-1(22). Figure 5A presents the relative levels of active phospho-GSK3β(Ser 390) in SHSY5Y cells that were untreated or treated with 35 µM 6-OHDA. 6-OHDA-treatment increased the relative levels of
active phospho-GSK3β by 5-fold and over-expression of SGK-1 reduced these levels 2-fold (Fig 5A). Conversely, the relative levels of Ser 9 phospho-GSK3β (representative of an inhibitory phosphorylation caused by SGK1) were very low in 35 µM 6-OHDA treated cells and increased to almost untreated control cell levels in SGK-1-infected cells even though they had been treated with 35 µM 6-OHDA (Fig 5B). In a similar manner to inhibitory GSK3β (Ser 9) Mcl-1 expression was reduced relative to control in the presence of 35 µM 6-OHDA and those levels were increased when SGK1 was over-expressed (Figure 5C). Similarly there was a corresponding increase in phosphorylated Mcl-1 levels (Figs. 5 D) in the presence of 35 µM 6-OHDA and those levels were increased when SGK1 was over-expressed (Figure 5D). Higher levels of GSK3β phosphorylated at Ser9 (Fig. 5 C) in these samples indicated that SGK1 inhibited the activation of GSK3-β, leading to reduced phospho-Mcl-1 levels. These data show a link between the neuroprotective role of SGK1 by which it inhibits the activation of GSK3β thereby restoring Mcl-1 levels in the cell.

SGK1 phosphorylated M KK4 at serine 80 and prevented activation of M KK4

MKK4 has been shown to activate JNK signaling and it also has been shown that MKK4 is phosphorylated at serine 80 by SGK1 and is subsequently inactivated (20, 37, 38). To confirm that MKK4 is indeed a substrate for SGK1, a Kinase-Glo™ assay was performed with increasing concentrations of recombinant inactive MKK4 and active SGK1 in the presence of 1 µM ATP (Fig. 6 A). Western blot analysis using these reaction mixtures confirmed MKK4 phosphorylation at serine 80 by activated SGK1 (Fig. 6 B). These in vitro data were corroborated by cell-based experiments looking at inhibition of MKK4 activity by SGK1 phosphorylation of Ser80 in MKK4. SH-SY5Y cells were treated with 6-OHDA to activate
MKK4 and consequently the JNK signaling pathway. Cells treated with 6-OHDA showed 12-fold higher levels of active MKK4 than control cells and over-expression of SGK-1 reduced the level of active MKK4 to background levels (Fig 6C). Cells that over-expressed SGK1 showed increased levels of phospho-MKK4 Ser80 (Fig 6D) and 6-OHDA treatment reduced these levels back to around baseline whereas over-expression of SGK-1, even in the presence of 6-OHDA, restored the phospho-MKK4 (Ser 80) levels indicative of full inactivation (Fig 6D). Activation of MKK7 was also seen for cells stressed with 6-OHDA but those levels were reduced in cells over-expressing SGK1 and treated with 6-OHDA as expected (Fig 6 E). Activation of MKK4 and MKK7 coincided with high phospho-JNK levels in cells treated with the neurotoxin (Fig. 6 F).

As a consequence of MKK4 and MKK7 inactivation in cells over-expressing SGK1, low levels of phospho-JNK were seen in these cells (Fig 6 F). Lowering of phospho-MKK7 levels in cells that over-expressed SGK1 could be due to the alleviation of overall stress in the cells, leading to cell survival and reduced activation of MKK7, instead of a direct inhibition by SGK1. These findings support the observed inhibition of Mcl-1 degradation as seen in Fig. 5 A and also demonstrates the contribution of SGK1 in disabling the MKK4-mediated JNK activation in neurons.

**SGK1 over-expression protects MPTP-induced TH cell death in substantia-nigra in C57BL/6J mice by inhibiting MKK4-mediated JNK activation**

To test whether the protective effects of SGK1 seen in vitro could be manifested in vivo, we assessed if SGK1 could block dopaminergic cell loss in the substantia nigra pars compacta (SNpc) of mice lesioned with MPTP. To do this, we stereotactically injected $1 \times 10^{10}$ AdV-SGK1 particles into the right striatum and gene expression was allowed to proceed for 21 days following which mice were challenged with an acute MPTP-lesion regimen as is described in
experimental procedures. Fig. 7 presents the YFP-SGK1 expression in the SNpc in the region of -3.0 bregma 28 days after injection into the striatum for both the saline treatment and the MPTP treated mouse. High level of YFP-SGK-1 expression was seen for both treatment groups, and this expression coincided with the TH immunoreactivity in the SNpc as seen in the merged panels. Fig. 8A shows immunohistochemical staining of TH neurons in SNpc for one representative mouse for each of the three groups. Fig 8B i, presents the unbiased stereological count for the number of TH<sup>+</sup> cells in the ipsilateral SNpc for three treatment groups as follows: saline/saline, saline/AdV-SGK1, saline/MPTP and AdV-SGK1/MPTP. As expected, the MPTP lesion reduced the number of TH<sup>+</sup> dopaminergic neurons by 50% compared with saline-treated or AdV-SGK1 injected animals (p < 0.05) and over-expression of SGK-1 restored those levels by ~40% (p < 0.05). Fig. 8B ii, shows that the total area measured in the SNpc following the MPTP lesion was the same for all groups. Increased TH<sup>+</sup> cell count in AdV-SGK1/MPTP group compared to saline/MPTP group indicated that neurons over-expressing SGK1 were protected from MPTP lesion (Figs. 8 A & B i). To test if the JNK pathway was activated by MPTP and subsequently protected by SGK-1 over expression we monitored various components of the pathway in vivo by Western analysis. Western immunoblot analysis of the SNpc tissue samples showed increased levels of phospho-MKK4 ser257/Thr261, phospho-MKK7 ser272/Thr275, phospho-JNK and phospho-c-Jun in MPTP treated group (Fig. 8 Ci). This increase was rescued in groups treated with AdV-SGK1 prior to the MPTP lesion. Control group showed lower levels of these active phosphorylated proteins. Phospho-MKK4 ser 78 (serine 80 in humans) levels, however, were low in MPTP-treated group compared to the AdV-SGK1+MPTP treated group. To corroborate the Western immunoblot findings we also looked at p-c-Jun levels by immunohistochemical analysis in the three treatment groups (Fig. 9). The data shows that p-c-
Jun levels were significantly increased in the SNpc and co-localize with TH neurons after MPTP treatment and that overexpression of SGK-1 modestly reduced those levels (Fig. 9) in a similar manner to that seen in the Western analysis. These results indicate that SGK1 inhibited M KK4 by phosphorylating it on serine 78 (serine 80 in humans) and consequently inhibited JNK activity in vivo and protected dopaminergic neurons from MPTP-induced death.

Discussion

The role of SGK1 in neurobiology has not been studied extensively and therefore very little is known regarding the details by which it confers neuroprotection. The JNK signaling pathway on the other hand has been well investigated in neurodegeneration and underscores the importance of JNK in the brain (15, 16, 18, 39, 40). The work presented here for the first time links the neuroprotective molecular components of SGK1 with the JNK signaling cascade in a PD neurotoxin cell and animal model.

Various studies have shown an upregulation of SGK1 as a cell survival response in transgenic models of PD and ALS (1–3, 25). In line with previously published data, in our study we too observed an increase in SGK1 expression at both mRNA and protein level and a corresponding increase in phosphorylated and activated levels of SGK1 in response to neurotoxic stress induced by 6-OHDA in SH-SY5Y cells and enabled us to utilize this neurotoxin cellular model to study SGK1 biology in neurodegeneration. Neuronal apoptosis has been shown to be accompanied and preceded by mitochondrial dysfunction (41) and our work here for the first time shows that induction of SGK1 expression had a direct affect on mitochondrial ROS production, mitochondrial membrane depolarization alleviation and protected cells from neurotoxin-induced death. Since SGK1 shares some its functions and substrates with Akt (6) it is not very
clear in much of the previously published data whether the neuroprotective effects seen are solely due to SGK1 expression or a combination of effects. Our studies showed that SGK1 over-expression likely compensated for the absence of Akt and therefore conferred protection in neuronal cells primed for apoptosis. Phosphorylation of SGK1 substrates NDRG1 and FoxO3a, one of which is shared with Akt, was shown to be augmented in our SGK1 over-expression cell model. These increases could either directly or indirectly lead to cell survival by regulating the transcription of key anti- and pro-apoptotic proteins and signaling pathways.

ER and mitochondrial stress are hallmarks of neuronal apoptosis, which are tightly regulated by various proteins responsible for cell survival and apoptosis. Proteins such as BiP, Hsp70 and SOD1, which were investigated in our study, are well-known indicators of ER and mitochondrial stress (28, 29, 32, 36) and their expression is critical for the progression of neuronal cell death. Expression levels of BiP and Hsp70 getting restored to normal levels and increases in SOD1 levels in our cellular neurodegeneration model when SGK1 expression was high, signified an essential role for SGK1 in relieving mitochondrial and ER stress by regulating the expression of these key cellular dysfunction marker proteins. These changes in expression levels for stress marker proteins could either be a direct or an indirect effect of SGK1 over-expression and will require further detailed study to elucidate whether SGK1 induces protection by directly interacting with these molecules or through its substrates, NDRG1 and FoxO3a.

Signaling cascades upstream of SGK1 are well studied, but insufficient information is available about downstream events in neurodegeneration. In order to delineate the neuroprotective effect of SGK1 in our neurotoxin models we investigated opposing signaling pathways that mediate cell survival and apoptosis involving SGK1 and JNK. Expression of anti-apoptotic protein Mcl-1 has been shown to decrease under cellular stress as it gets phosphorylated by JNK and
subsequently by GSK3β, priming it for degradation (23). Our findings supported these observations and showed that SGK1 over-expression in SH-SY5Y cells rescued the degradation of the pro-survival protein Mcl-1 which was accompanied by a marked decrease in the activated levels of its kinases GSK3β and JNK. Rescue of Mcl-1 protein degradation and inactivation of GSK3β by SGK1 over-expression indicates a crosstalk between the cell survival and apoptotic pathways that are underway in these neurons. Stressed cells are veered towards the pro-survival pathway when there is more SGK1 to inactivate GSK3β and JNK, consequently restoring Mcl-1 levels and cell viability.

The data from our study suggests a role for SGK1 in protecting neuroblastoma cells from neurotoxic cell death by alleviating mitochondrial dysfunction and by regulating the expression of ER and mitochondrial stress marker proteins. It does so by suppressing well-known pro-apoptotic signaling cascades. JNK activation by MKK4 during cellular stress is well known (38). Our biochemical and cell-based experiments corroborated previous studies that show phosphorylation of MKK4 by SGK1 (20). Our results showed that SGK1 over-expression in 6-OHDA treated or untreated SH-SY5Y cells triggered significant increases in phosphorylation of MKK4 at serine80 and inhibited its activity in these cells as was shown by lower phospho-JNK levels. Higher levels of inhibited phospho-MKK4 Ser80 levels found in cells over-expressing SGK1 and treated with the neurotoxin, indicated that SGK1 inhibited MKK4 activity, which in turn inhibited activation of the JNK signaling cascade. SGK1 mediated-JNK inactivation also explains the rescue of Mcl-1 degradation in cells treated with SGK1 adenovirus prior to stress. These experiments demonstrated a more direct role of SGK1 in JNK inactivation, which also supports the observation of augmented Mcl-1 levels in stressed cells with increased SGK1 activity and rescue of cellular stress on the whole. Chen et al., showed in a 6-OHDA PD mice
model that over-expressing SGK1 in the mesencephalic dopamine neurons protected neurons from 6-OHDA-induced apoptosis (13). We attempted to test this observation in a MPTP mouse model. Our in vivo findings corroborated the 6-OHDA finding from Chen et al. as well as our cell-based findings, where we found that by inducing the expression of SGK1 using the adenoviral vector transfer, the dopaminergic neurons could be protected from MPTP lesion. This observation was accompanied by an increased expression of phospho-MKK4 Ser78 (Ser80 in humans) levels and as a result reduced JNK activity as seen by reduced levels of phospho-JNK and its nuclear product, phospho-c-Jun.

Through a series of in vitro and in vivo studies we have begun to elucidate the molecular contributors to cytoprotection by SGK1. Our data suggests the following proposed contributions to SGK1 signaling and cell survival: First, over-expression of SGK1 caused inactivating phosphorylation on GSK3β, and MKK4, as well as phosphorylation of FoxO3a and NDRG-1. The inactivation of MKK4 subsequently caused an inactivation of JNK. The inactivation of GSK3β along with the lack of JNK activation caused Mcl-1 not to be phosphorylated, preventing it from being degraded and thus promoting cell survival. In addition the phosphorylation on FoxO3a and NDRG-1 also served to be neuroprotective thereby promoting cell survival (Fig 10).

The data also suggests that even though the levels of endogenous SGK1 increases in the cell under stress, it is not sufficient to promote cell survival in our neurodegeneration model. On the other hand, cell survival mechanisms dominate when exogenous SGK1 is added to the neuronal cells. However, careful observations must be made for the differences in cellular signaling outcomes for different pathologies affecting tissues involving SGK1 activation or over-expression.
Collectively our findings help to further define the underlying pathogenic mechanisms in neurodegeneration models where complex I deficiencies and mitochondrial dysfunction may be the underlying source for dopaminergic neuronal death. This work elucidated the interplay of various apoptotic and cell survival mechanisms involving SGK1 and JNK in neurotoxin-induced cellular stress conditions and an up-regulation of survival pathways in these cells significantly reduced apoptosis in neurons. Additional studies need to be undertaken to further dissect the role of SGK1 in JNK and other cell death signaling cascades so that this molecular understanding of protein interactions and modulations could be exploited in developing small molecule SGK1 activators that would promote cell survival in neurodegeneration.
References


Acknowledgements: This work was supported by DOD grant W81XWH-12-1-0431, NIH grant U01-NS057153, NIH grant GM103825, the Michael J Fox Foundation/23&Me, the Saul and Theresa Esman Foundation, and a gift from the McCubbin Family.
Figure 1

A. 35 μM 6-OHDA

B. 35 μM 6-OHDA

- Endogenous SGK1
- Endogenous phospho-SGK1 (ser 80)
- α-Tubulin

C. % Mito Xen Fluorescence

- Mock
- 10 μM DEX
- PBS
- 10 μM DEX + 500 μM 8-BrcA

D. Normalized percent Depolarized Mitochondria

- Mock
- 10 μM DEX
- PBS
- 10 μM DEX + 500 μM 8-BrcA

E. % cell viability

- Mock
- 10 μM DEX
- PBS
- 10 μM DEX + Akt Inhibitor

F. 35 μM 6-OHDA

- Untreated cells
- Akt Inhibitor/MK-2206

- MW
- 50 phospho-Akt
- 72 α-tubulin
Figure 2

35 μM 6-OHDA

A.

B.

C.

D.
Figure 6

A. Normalized MEK2 phosphorylation by SGK1.

B. M KK4  +  +  +  +  +
1 μM ATP  -  -  -  +  -
10 μM ATP  -  +  -  -  +
SGK1  -  -  +  +  +
phospho-MKK4
ser80

C. Phospho-MKK4 Ser257/Thr251
Control, APV-SOGK, PBS, APV-SOGK

D. Phospho-MKK4 Ser80
Control, APV-SOGK, PBS, APV-SOGK

E. Phospho-JNK1/2/3 (Ser62,Ser76,Tyr70)
Control, APV-SOGK, PBS, APV-SOGK

F. Phospho-JNK1/2/3 (Ser62,Ser76,Tyr70)
Control, APV-SOGK, PBS, APV-SOGK
Figure 10

Neurotoxic stress (e.g., 6-OHDA, MPTP)

SGK1

GSK3β

MKK4

NDRG-1

FOXO3a

INK

MD-1

Cytoprotection (cell survival)

Cell death mechanism

Cell survival mechanism
Figure legends

Figure 1. SGK1 is upregulated in response to neurotoxic stress and its over-expression induced by Dexamethasone rescues 6-OHDA-mediated cell death and mitochondrial dysfunction in SH-SY5Y cells. A) SGK1 mRNA expression profile showed an increase in expression on treatment with 35 µM 6-OHDA over time. (B) Western immunoblot analysis showed that endogenous SGK1 expression is upregulated and phosphorylated in response to cellular stress, such as 6-OHDA. (C, D, E) SGK1 expression was induced by adding 10 µM dexamethasone (Dex) to SHSY5Y cells 24 h prior to 6-OHDA treatment. 35 µM 6-OHDA was used to induce mitochondrial dysfunction and cell death. Mitochondrial superoxide production C), membrane depolarization D) and cell death E) was monitored in SH-SY5Y cells and protection by SGK1 was compared to protection from a selective JNK inhibitor. F) An allosteric Akt inhibitor, MK-2206 was used. DMSO was used as small molecule control. Data presented in this figure represents measurements from three biological replicates with three samples per replicate. Statistical significance (p<0.05) was determined using a Student’s t-test. Differences between 6-OHDA and mock or Dex-treated cells are shown by a single asterisk (*). Differences between 6-OHDA and Dex+6-OHDA or 6-OHDA and Dex+ Akt inhibitor+6-OHDA treatment groups are shown by a double asterisk (**).

Figure 2. Adenoviral-mediated over-expression of SGK1 rescued 6-OHDA-induced mitochondrial superoxide production, membrane depolarization and cell death. SHSY5Y cells were infected with AdV-SGK1 with an MOI of 5 and were incubated at 37°C and 5% CO2 for 48 h for protein expression. Cells were then treated with 35 µM of 6-OHDA for 5 h. Mock GFP-infected cells were used as cellular background control, while DMSO was used as small molecule control. Mitochondrial superoxide production was monitored by MitoSOX™ Red.
staining for both live cell imaging A) and a quantitative measure B) JC-1 staining was used to measure mitochondrial membrane depolarization C), and cell death was measured by using MTT cell viability assay D). Data presented represent measurements from three biological replicates with three samples per replicate. Statistical significance (p<0.05) was determined using a Student’s t-test. Differences between 6-OHDA and mock or AdV-SGK1-treated cells is shown by a single asterisk (*) and differences between 6-OHDA and AdV-SGK1+6-OHDA or 6-OHDA and AdV-SGK1+ Akt inhibitor+6-OHDA treatment groups is shown by a double asterisk (**).

**Figure 3.** Over-expression of SGK1 rescues 6-OHDA-induced expression of cellular stress marker proteins in SH-SY5Y cells. SH-SY5Y cells were infected with AdV-SGK1 adenovirus or treated with 10 µM of dexamethasone (Dex) to induce SGK1 expression and cell lysates were examined for BiP A), Hsp70 B) and SOD1 C) expression. α-Tubulin was used as a loading control. BiP, Hsp70 and SOD1 expression was also monitored in 6-OHDA treated cells treated with 500 nM of JNK inhibitor SR-3306. AdV-GFP was used as a control for AdV-SGK1 infection. Data presented here are representative Western blots of three biological replicates.

**Figure 4.** Western immunoblot analysis for phosphorylation of the SGK1 substrates, NDRG-1 and FoxO3a in cells over-expressing SGK1. SH-SY5Y cells were infected with AdV-SGK1 and incubated for 48 h for protein expression as described in Experimental procedures. α-tubulin is shown as a loading control. Data presented is one representative Western blots from three biological replicates.
Figure 5. SGK1 rescued the degradation of cell survival protein Mcl-1 and its phosphorylation by inactivating GSK3β in SH-SY5Y cells. A) Ratio of GSK3β serine 390 phosphorylation/α-tubulin levels under different cell treatment conditions. B) Ratio of phospho-GSK3β ser9/α-tubulin levels under different cell treatment conditions. C) Ratio of Mcl-1/α-tubulin levels under different cell treatment conditions. D) Ratio of phospho-Mcl-1/α-tubulin levels under different cell treatment conditions. Cells were either untreated, untreated with AdV-SGK-1 infection, PBS control treated with 35 µM 6-OHDA, or treated with 35 µM 6-OHDA infected with AdV-SGK-1.

Figure 6. Effect of SGK1 expression on the phosphorylation state of MKK4, MKK7, and JNK in the presence and absence of 6-OHDA in vitro. A) Kinase Glo™ assay was performed using 0.75 µM active SGK1 protein and different concentrations of inactive MKK4 (0-10 µM) in the presence of 1 µM ATP. MKK7 protein was used as negative control in this assay and as expected showed no phosphorylation in the presence of active SGK1 and ATP. (B) Western immunoblot analysis for phosphorylation of MKK4 on serine 80 by active SGK1 in the presence of 1 µM and 10 µM ATP. C) Western immunoblot analysis of the ratio of phospho-MKK4 Ser257/Thr261/α-tubulin from SH-SY5Y cells untreated and treated with 35 µM 6-OHDA in the presence and absence of AdV-SGK-1. D) Western immunoblot analysis of the ratio of phospho-MKK4 Ser80/α-tubulin from SH-SY5Y cells untreated and treated with 35 µM 6-OHDA in the presence and absence of AdV-SGK-1. E) Western immunoblot analysis of the ratio of phospho-MKK7Ser271/Thr275/α-tubulin from SH-SY5Y cells untreated and treated with 35 µM 6-OHDA in the presence and absence of AdV-SGK-1. F) Western immunoblot analysis of the ratio of phospho-JNK/α-tubulin from SH-SY5Y cells untreated and treated with 35 µM 6-OHDA in the presence and absence of AdV-SGK-1.
the presence and absence of AdV-SGK-1. Expression levels of MKK4, MKK7 and JNK did not change significantly between different treatments (data not shown).

**Figure 7. YFP-SGK1 Overexpression in the SNpc after 28 days.** AdV-YFP-SGK1 was injected into the striatum of mice treated with saline or treated with MPTP and 28 days later YFP-SGK1 expression was assessed. TH immunohistochemistry for a representative saline–treated mouse, and an MPTP-treated mouse where AdV-SGK1 was over-expressed for 21 days prior to MPTP treatment. 1x10¹⁰ viral particles of AdV-SGK1 were injected into the striatum 21 days prior to an acute treatment regimen of 18 mg/Kg MPTP (1 doses every two hours for 4 doses).

**Figure 8. SGK1 over-expression protected MPTP-induced dopaminergic neuronal cell death in the substantia-nigra in C57BL/6J mice by inhibiting MKK4-mediated JNK activation.** A) TH immunohistochemistry for a representative saline–treated mouse, an MPTP-treated mouse, and an MPTP-treated mouse where AdV-SGK1 was over-expressed for 21 days prior to MPTP treatment. 1x10¹⁰ viral particles of AdV-SGK1 were injected into the striatum 21 days prior to an acute treatment regimen of 18 mg/Kg MPTP (1 doses every two hours for 4 doses). B (i) Stereological quantification of TH positive neurons in different treatment groups, B (ii) Measured volume of midbrain section used for the TH neuron analysis. C (i) Western immunoblot analysis of phospho-SGK-1, phospho-MKK4 ser257/ Thr261, phosphor-MKK4 Ser 78, phospho-JNK and phospho-c-Jun in midbrains treated with saline, saline/MPTP, and MPTP/AdV-SGK-1. (ii) Quantitated normalized expression to α-tubulin for the proteins and sample treatments described in C (i).
Figure 9. Phospho-c-Jun (p-c-Jun) Immunohistochemical analysis in the substantia-nigra in C57BL/6J mice. p-c-Jun immunohistochemistry (red) for a representative saline-treated mouse, an MPTP-treated mouse, and an MPTP-treated mouse where AdV-SGK1 was over-expressed for 21 days prior to MPTP treatment. TH immunohistochemistry (green) for a representative saline-treated mouse, an MPTP-treated mouse, and an MPTP-treated mouse where AdV-SGK1 was over-expressed for 21 days prior to MPTP treatment. 1x10^10 viral particles of AdV-SGK1 were injected into the striatum 21 days prior to an acute treatment regimen of 18 mg/Kg MPTP (1 doses every two hours for 4 doses).

Figure 10. Molecular mechanism for SGK1 signaling and cell survival